Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States

BACKGROUND: Limited data are available about the real‐world safety of non‐vitamin K antagonist oral anticoagulants (NOACs). OBJECTIVES: To compare the major bleeding risk among newly anticoagulated non‐valvular atrial fibrillation (NVAF) patients initiating apixaban, warfarin, dabigatran or rivaroxa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lip, Gregory Y. H., Pan, Xianying, Kamble, Shital, Kawabata, Hugh, Mardekian, Jack, Masseria, Cristina, Bruno, Amanda, Phatak, Hemant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129572/
https://www.ncbi.nlm.nih.gov/pubmed/27550177
http://dx.doi.org/10.1111/ijcp.12863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129572/
https://www.ncbi.nlm.nih.gov/pubmed/27550177
http://dx.doi.org/10.1111/ijcp.12863

Ejemplares similares